Mandibular Reconstruction With a Recombinant Bone-Inducing Factor: Functional, Histologic, and Biomechanical Evaluation

Toriumi, Dean M.; Kotler, Howard S.; Luxenberg, Deborah; Holtrop, Marijke; Wang, Elizabeth A.

doi:10.1001/archotol.1991.01870220049009

Cited by 343 publications

(125 citation statements)

References 17 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…The results of this study provide evidence of the safety and technical feasibility of TEB for maxillary sinus floor augmentation and vertical ridge augmentation in agreement with those from earlier animal studies that have indicated that treatment with TEB dose not result in toxicity, significant immunologic reactions, or other serious adverse effects [20][21][22][23] .…”

Section: Figsupporting

confidence: 88%

Tissue engineered bone; Application for implant surgery

Ueda

2011

Inflammation and Regeneration

View full text Add to dashboard Cite

Section: Figsupporting

confidence: 88%

Tissue engineered bone; Application for implant surgery

Ueda

2011

Inflammation and Regeneration

View full text Add to dashboard Cite

“…Among graft materials currently available for clinical use, autogeneous cancellous bone is the most effective in stimulating bone healing response. However, autografting requires additional surgical procedures resulting in increased morbidity and operative time [4,11,22], and in some cases, the quantity of bone available for harvest is insufficient. Vascularized autografts need special techniques for microvascular tissue transfer [11,20].…”

Section: Discussionmentioning

confidence: 99%

“…Although various bone graft techniques have been established [18][19][20], there are disadvantages to each such as additional surgical invasion and limited bone source in autograft, immunomediated rejection and transmission of infectious agents in allograft or xenografts, and technical difficulty in vascularized grafts. Recently, therefore much interest has been focused on the application of bone morphogenetic protein (BMP) as a bone graft substitute in reconstructive orthopedic surgery [4,5,9,11,15,22].…”

Section: Methodsmentioning

confidence: 99%

“…osteogenic activity in rodents [16], and promising results using rhBMP-2 or rhBMP-7 in bone defect healing have been reported in dogs [4,22].…”

mentioning

confidence: 99%

“…The carrier can determine the shape and size of induced bone, which is important to the induction of new bone at confined sites such as bone defect or nonunion fracture sites. In previous reports on bone healing by rhBMPs [4,5,22], insoluble bone matrix (IBM) was used as a carrier of rhBMP. However, IBM may possibly contain some unknown factors and xenogeneic IBM restricts the clinical application of rhBMP [5,7].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Repair of Ulnar Segmental Defect by Recombinant Human Bone Morphogenetic Protein-2 in Dogs.

Itoh

Mochizuki

Nishimura

et al. 1998

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. The efficacy of recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with poly D, L lactic-co-glycolic acid (PLGA)/gelatin sponge complex (PGS) as a carrier on the repair of segmental long-bone defects was evaluated using an ulnar model in dogs. The defect was 2 cm in length and was fixed with bone plating. After implantation of PGS with or without rhBMP-2, the repair process of the defect was evaluated by serial radiography until 16 postoperative weeks. All defects treated with 160 µg or 640 µg of rhBMP-2/PGS revealed bone union radiographically by 12 postoperative weeks, whereas all defects treated with PGS alone revealed no radiographic evidence of healing throughout the experimental period. In defects treated with 40 µg of rhBMP-2/PGS, new bone appeared partially at the defects but did not accomplish union. Bone mineral contents at the defect sites after harvest at 16 weeks postoperatively were significantly (p<0.05) higher in those treated with 160 µg or 640 µg of rhBMP-2 than in those treated with 40 µg of rhBMP-2 or PGS alone. Histologically, defects radiographically diagnosed as having achieved union showed the appearance of cortical bone and bone marrow cells. These findings suggest the use of rhBMP-2/PGS as a potential bone graft substitute in reconstructive surgery in dogs. -KEY WORDS: canine, rhBMP-2, ulnar defect.

show abstract